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Key messages
• Noncommunicable diseases (NCDs) and mental disorders
are the leading contributors to disease burden in the
WHO European Region
• This burden can to some extent be avoided through
investing in evidence-informed health promotion or
disease prevention interventions within and beyond the
health system
• There is a substantial evidence base suggesting that many
health promotion and disease prevention interventions,
delivered within the health system as well as in
partnership with other sectors, are highly cost-effective,
although very little of this evidence is from the eastern
part of the WHO European Region
• Despite this evidence, the level of investment in health
promotion and disease activities remains stubbornly low
in many countries
• Ministries of health as well as ministries of finance can
play pivotal roles in increasing investment within and
outside the health system; however, simply increasing the
volume of economic evidence is unlikely to make a
dramatic impact on overall levels of investment
• Barriers to investing are many and include scepticism over
the effectiveness of interventions and the reluctance to
invest in actions which decision-makers may think will not
generate positive benefits for many years
• However, there are important contributions that
economics can directly make:
– More evidence should be generated on the economic
benefits of interventions with short, as well as mid and
long-term returns on investment
– More evidence is also needed on economic benefits in
different country contexts, taking account of the
challenges of implementation and equity implications 
– Return on investment models can be used, alongside
conventional economic evaluation methods, to
communicate economic costs and benefits to different
sectors over different time scales
• There also needs to be a much greater focus on the way
in which evidence is communicated with policy-makers;
this includes placing more attention on identifying and
communicating the economic benefits of better non-
health specific outcomes measures when the health
sector seeks to influence or work with other sectors
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Executive summary
The 2008 Tallinn Charter: Health Systems for Health and
Wealth recognized that investing in health means investing
in human development, social well-being and wealth. It
stated that ‘health systems are more than health care and
include disease prevention, health promotion and efforts to
influence other sectors to address health concerns in their
policies’. Ten years on, investment in health promotion
and disease prevention activities, at least within the
health sector, remains stubbornly low in many
countries. For instance, OECD countries typically allocate
between 2% and 4% of total health sector spending to
these activities. Moreover, between 2009/2010 and
2012/2013 on average spending fell in real terms and still in
2014/2015 was only growing at around 2% per annum, a
rate that is much lower than before the onset of the global
economic crisis.
There are many different reasons for this, but undoubtedly
some budget holders in health systems are sceptical
about the case for focusing more on public health,
contending that there is insufficient evidence available to
justify such an investment. In this policy brief we argue that
this scepticism about the evidence is overstated. Moreover,
the existing evidence base can in fact be adapted to be
useful in many different systems and country contexts across
the WHO European Region.
Potential economic benefits 
of addressing disease burden
The 10 leading contributors to disease burden in the
WHO European Region in 2015 were all NCDs or
mental disorders. All of these conditions are amenable to
health promotion and disease prevention interventions. They
include actions to reduce the lifetime risks of Alzheimer’s
disease and other dementias that have now become leading
contributors to the disease burden.
These conditions not only translate into health care costs
but also have broader personal, social and economic
costs. Indeed much of the costs of poor health fall outside
health care systems, for example 45% of the costs of
cardiovascular diseases and 59% of the costs of major
depression. This is due to productivity losses mainly arising
from greater levels of sickness absence and premature
withdrawal from the labour market because of chronic
health problems over the life-course. Back/neck pain and
depressive disorders, the leading reasons for years lived with
disability (YLDs), are also leading reasons for long-term
sickness absence from employment and premature
retirement.
All of these conditions, as well as injuries, should to some
extent be avoidable through investment in evidence-
based actions to counter risks to health, including
interventions to help change lifestyles, as well as measures
to ensure more safe and healthy living and working
environments and to tackle socioeconomic inequalities. Risks
to health associated with the most common behavioural risk
factors (smoking, harmful drinking, a lack of physical activity
and poor diet) impact directly on all 10 of the leading
contributors to the burden of disease in 2015. 
There is an economic case for investment
Economic arguments have been used successfully to help
influence the ways in which health and other policy-makers
allocate resources to health care and public health
programmes in many country contexts. Illustrative
examples of the case for action within and outside health
care systems were identified in recent literature reviews.
Within health care systems these include brief physician
advice interventions, such as those to protect the mental
health of people with physical health problems and
screening programmes for hazardous drinking. 
Many of the risks to health are addressed through cost-
effective actions delivered outside health systems. They
include the use of taxation and other fiscal measures,
restrictions on retail access and advertising, as well as media
campaigns, to reduce risks from harmful behaviours
including tobacco and alcohol consumption. Packages
combining measures within the health care system such as
brief advice interventions, alongside some of these measures
in other sectors, are likely to be more cost-effective than
individual measures in isolation. Combining some of these
measures, alongside initiatives such as product reformulation
and increased opportunities for physical activity, for example
by investing in cycling schemes, can also be cost-effective in
different contexts when looking to influence diet and
physical activity.
Other illustrative examples include early intervention during
the perinatal period to support mothers and their infants.
Health systems can work with schools to promote cost-
effective emotional resilience, better health literacy and
anti-bullying measures targeted at children. Health systems
can also benefit by collaborating with workplaces,
particularly small- and medium-sized workplaces that may
have limited occupational health services to promote
physical and mental well-being in the workplace. There is
also a strong economic case for the health sector to
continue to work with the transport and justice sectors, as
well as the automobile industry, for enhanced enforcement
of safety measures such as traffic calming and speed
reduction measures, increased use of seat belts and more
safety features installed into vehicles, all of which can be
cost saving.
What we do not know
While there is a sound economic case for investing in
measures to promote health and prevent disease and injury,
methods used in economic evaluation differ, making
comparisons between studies difficult. There are also
many gaps in the evidence base, including much less
information on the economic case for action in the eastern
part of the WHO European Region and a need for more
on interventions with short-term as well as long-term
impacts. Little is known about the economic case for
investing in many behavioural psychology influenced
interventions despite their raised profile in recent years.
Moreover, much of the existing literature does not directly
look at the equity implications of interventions; this is
also important to evaluate in order to reduce the risk of
inadvertently widening health inequalities by failing to reach
those segments of the population in most need.
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However, simply increasing the volume of economic
evidence is unlikely to be sufficient to make a dramatic
impact on overall levels of investment. This requires much
more attention to be placed on the way in which
evidence can be translated into practice. Ministries of
health as well as ministries of finance can play pivotal roles
in incentivizing different actors within and outside the health
system to invest in disease prevention. Some of this is about
implementation and political science, but there are
important contributions that economics can directly make.
These include devoting more efforts to the generation of
return on investment analyses that place as much (if not
more) emphasis on the value of non-health benefits to
sectors that the health system wishes to influence or partner
with. This needs to go beyond a focus solely on benefits to
ministries of finance but should consider how best to work
with many more sectors, such as housing, education,
social welfare, justice and transport. It also involves
collaborating with occupational health services in the public
and private sectors. Financial and other economic incentives,
as well as contracts and other regulatory arrangements, can
be used to stimulate new partnerships and shared budgets
between the health system and other sectors. The same
approach might also be used to stimulate even more
partnerships working between public health professionals
and other actors within health systems.
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The 2008 Tallinn Charter: Health Systems for Health and
Wealth recognized that investing in health means investing
in human development, social well-being and wealth. It also
stated that ‘health systems are more than health care and
include disease prevention, health promotion and efforts to
influence other sectors to address health concerns in their
policies’[1].
Ten years on, investment in health promotion and disease
activities, at least within the health system, remains
stubbornly low in many countries. There are many different
reasons for this, but some budget holders in health systems
remain sceptical about the case for focusing more on public
health, contending that there is insufficient evidence
available to justify such an investment. They may further
argue that, even when evidence is available, it is not relevant
to their local context, and may serve only to divert valuable
resources away from clinical activity where more health
benefits to society can be realized. Health promotion and
disease prevention budgets are among the most vulnerable
areas of health system spending when resources are tight.
Some health care service providers may even be fearful of
their own security should more resources be diverted to
public health, especially at a time when public sector
spending in many countries in the WHO European Region
remains under great pressure.
In this policy brief we argue that this scepticism over the
evidence is overstated; moreover, that this evidence base can
also be adapted to be useful in many different systems and
country contexts across the WHO European Region.
Throughout the brief we also recognize that investing in
health requires investment in health promotion and disease
prevention, both within and outside the health system,
because our health is influenced by many different factors,
not all of which can be addressed by health care
professionals. Our health is partly determined by our genes,
while access to and the quality of health care services also
play a critical role. Yet much of our health is dependent on
‘upstream’ risk factors. These include health behaviours,
such as our levels of physical activity and our diets, as well as
environmental factors, including our working and school
environments. Our levels of education, socioeconomic
status, including poverty rates and income inequalities, are
also critical. Nor can we overlook differences in cultural
values, attitudes to gender and ageing, as well as social
cohesiveness in different country settings, as these may also
impact on the ways in which populations engage with
health promotion and disease prevention activities.
Given that the health system on its own cannot cover all
aspects of disease prevention, it is also essential to have
convincing arguments to sustain actions outside the health
system. It is about identifying common objectives and goals
with other sectors. This means prioritizing the language and
relevant impacts to those sectors rather than just
communicating about health benefits. Yet health systems
have not always been effective in communicating sector
specific benefits, for example improved school performance
and classroom atmosphere that arise from school-based
health promotion actions. Nor do they highlight often
enough spillover benefits from health promoting actions in
one sector, for example education, that positively affect
another.
One example of this could be investing in school-based
mental health promotion and supported education
programmes, which in turn can help reduce the risk of
young people ending up not in education, employment or
training (NEET) when they reach adulthood. Around 15% of
young people aged 15-29 in the EU alone fall into this
category [2]. Reducing the level of NEETs in Europe in turn
should have benefits for welfare systems and more broadly
for economic productivity [2].
Therefore in the brief we first set out the current challenge,
looking at changing patterns in disease burden, all of which
are amenable to public health actions. We then set out why
alleviating some of this burden can have economic benefits
and how these benefits can be assessed. We describe some
of the different types of actions that can be taken and
provide illustrations of some that are either cost saving or
highly cost-effective in different contexts. The strengths and
limitations of approaches used to generate this evidence
base are then considered before we conclude by returning
to some of the challenges that have hindered
implementation and suggesting ways in which these
challenges may be overcome.
What do we know about overall disease burden 
in the WHO European Region?
The 10 leading contributors to the total burden of
disease in the WHO European Region are NCDs or
mental disorders
Before looking at the economic case for investment, first, let
us look at the changing nature of the burden of disease.
Figure 1 shows the 10 leading contributors to the total
burden of disease in 2015 and 2000 in the WHO European
Region (measured using disability-adjusted life years (DALYs),
which take account of morbidity and mortality). In 2015
these were all NCDs and mental disorders, with the top
three contributors being ischaemic heart disease, stroke and
back/neck pain. 
The most striking trends over the last 15 years are 
the emergence of Alzheimer’s disease among these 
10 main contributors and the fall in the burden of road
traffic injuries 
The relative importance of these risk factors vary from
country to country across the WHO European Region, but
the top two contributors to disease burden, ischaemic heart
disease and stroke, remain unchanged although they
accounted for a slightly lower share of disease burden,
21.3%, in 2015 compared with 24.5% in 2000. Overall, the
most striking change over this 15-year period has been the
emergence of Alzheimer’s disease and other dementias as
one of the leading contributors to disease burden. This
group of dementias only accounted for 1.1% of disease
burden in 2000 compared with 2.4% of total disease
burden in 2015; it is likely to increase further as a share of
disease burden as the European population ages, bringing
new challenges for public health policy. Yet at least 35% of
the risk factors for dementia are potentially modifiable
across the life-course [3]. Other notable changes at a
European Regional level include the fall in the burden of
road traffic injuries from 2.7% of disease burden in 2000 to
1.7% of disease burden by 2015 (ranking 12th in 2015
compared to 7th in 2000), while diabetes has increased to
2.6% of total burden (ranking 5th) in 2015 from 1.9% in
2000 (ranking 11th).
Introduction
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Figure 2 shows the number of years lived with disability
(YLDs) due to disease and injury in 2000 and 2015. There
has been no change in the leading contributors over this
time period, with back/neck pain and depressive disorders
together accounting for 18.6% of all YLDs in 2015
compared to 18.2% in 2000. Anxiety disorders also still
feature; another reminder of the importance of actions to
prevent mental as well as physical health problems, while
fall-related injuries also remain in the top 10 YLDs, being
particularly an issue among older people.
DALYs and YLDs are not just issues for health systems. As we
illustrate in a later section of this brief, they have profound
economic impacts, much of which, from a societal
perspective, fall outside the health care system, mainly by
affecting participation in employment and other paid and
unpaid productive activities by people of all ages. For
instance, back/neck pain and depressive disorders are
leading reasons for long-term sickness absence from
employment and premature retirement. There are also
impacts on the economic productivity of family members
who need to devote time and energy to supporting loved
ones living with health problems. This is a particular
challenge now in Europe given the rise in the number of
cases of diagnosed dementia, as this group of diseases often
places a great and long-lasting strain on families, to say
nothing of the impacts on social and long-term care services.
All of these disease burdens are to some extent
avoidable through investing in evidence-based health
promotion or disease prevention interventions
All of these burdens (and many others, including injuries)
should to some extent be avoidable through investing in
evidence-based actions to counter risks to health, including
interventions to help change lifestyles, as well as measures
to ensure more safe and healthy living and working
environments and tackling socioeconomic inequalities. It is
also important to be mindful of inequalities linked to gender,
ethnicity and culture, for instance to tackle the substantial
and persistent differences in life expectancy by gender
between the eastern and western parts of the WHO
European Region. Risks to health associated with the most
common behavioural risk factors, smoking, harmful
drinking, a lack of physical activity and poor diet, impact
directly on all 10 of the leading contributors to disease
burden in 2015.  
What are the costs of avoidable poor health?
Effective interventions that could avoid a tiny fraction
of these health problems might help substantially
boost economic output in the region 
While estimates of costs vary due to inconsistency in how
studies measure and report costs, there is no doubt that the
costs of poor health are enormous and long-lasting.
Figure 1: Percentage of total DALYs in WHO European Region, 10 leading contributors of disease burden 2015
and their contribution in 2000 
Source:  Adapted from [4]
2000 2015
Ischaemic heart disease (1) 16.1 14.8 (1) Ischaemic heart disease
Stroke (2) 8.4 6.8 (2) Stroke
Trachea, bronchus, lung cancers (3) 3.0 3.5 (3) Back and neck pain
Back and neck pain (4) 2.9 3.4 (4) Trachea, bronchus, lung cancers
Lower respiratory infections (5) 2.6 2.6 (5) Diabetes mellitus
Self-harm (6) 2.4 2.6 (6) Depressive disorders
Road traffic injuries (7) 2.4 2.4 (7) Alzheimer’s disease and other dementias
Chronic obstructive pulmonary disease (8) 2.3 2.2 (8) Chronic obstructive pulmonary disease
Depressive disorders (9) 2.2 2.1 (9) Lower respiratory infections
Falls (10) 2.0 1.9 (10) Colon and rectum cancers
Diabetes mellitus (11) 1.9 1.9 (11) Self-harm
Colon and rectum cancers (15) 1.6 1.7 (12) Road traffic injuries
and other dementias (24) 1.1 1.7 (13) Falls
Alzheimer’s disease
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Furthermore, much of these costs are incurred beyond the
boundaries of the health system, including lost productivity in
the workforce, as well as lost human capital acquisition and
future productivity as a result of poor performance while at
school. For example in the WHO European Region it has been
estimated that productivity costs accounted for 45% of all the
annual costs associated with cardiovascular diseases [6], while
for depression in western Europe1 productivity losses have
been estimated to account for 59% of total costs [7].
The WHO’s EPIC (Projecting the Economic Cost of Ill-health)
tool can be used to calculate the value of economic lost
output due to illness, including impacts on health care
consumption and lost productivity. One analysis estimated
overall costs for five disease categories in high-income
countries between 2011 and 2030: diabetes, cardiovascular
diseases, chronic respiratory disease, cancer and mental illness
[6]. They incurred costs of $25.5 trillion, with 35%
($9.0 trillion) due to mental illness, and 33% ($8.5 trillion)
due to cardiovascular diseases. To put these very large figures
into context – the entire economic output of the European
Union (EU) in 2016 was approximately $17.8 trillion. 
As well as estimates of the economic costs of different
diseases, some of the costs associated with poor health
behaviours have been estimated. Again, these estimates may
be made in different ways, so caution should be exercised in
making direct comparisons between studies. Nonetheless, the
potential economic benefits of directly addressing some of the
upstream risk factors for poor health can be seen by looking
at impacts on costs, as well as on life expectancy and
premature mortality. Alcohol consumption has been
estimated to cost some 2–3% of gross domestic product
(GDP), mostly from lost productivity [8], a figure likely to
double if the costs to people other than the drinker are
included [9]. Smoking is the cause of 1.25 million deaths in
Europe each year, around 21% of all deaths. There is at least
a 10-year difference in life expectancy between current
smokers and those who have never smoked [10]. Even if
smokers stop smoking between the ages of 55 and 65 they
can still gain four years of additional life expectancy compared
to individuals who continue to smoke. All of these additional
years of life gained potentially add to economic output in the
region.
Physical inactivity is also a major risk factor for obesity and
other poor physical and mental health and premature
mortality; one detailed economic analysis estimated total
health-related costs in the WHO European Region in 2013 to
be $11.7 billion with a further $3.8 billion in lost productivity
as a result of poor health [11]. Unhealthy diets, particularly
those involving an excessive consumption of salt, sugar and
fat, energy-dense, nutrient-poor foods and sugary drinks, as
well as limited intake of fruit and vegetables and whole-
grains, also contribute to NCDs, including the major disease
burden in Europe from cardiovascular diseases, stroke, some
cancers and diabetes. 
In all European countries therefore, economic benefits within
and outside health systems can potentially be realized if some
of this burden of disease can be avoided. Effective disease
prevention measures that reduce the burden by a tiny fraction
might not only reduce pressure on health systems but also
potentially boost economic output in the region. 
Figure 2:  Percentage of total YLDs in the WHO European Region, 10 leading contributors in 2015 and their contribution in 2000
Source:  Adapted from [5]
1 All EU countries except Croatia, plus Iceland, Norway and Switzerland.
2000 2015
Back and neck pain (1 ) 10.4 10.7 (1) Back and neck pain
Depressive disorders (2) 7.8 7.9 (2) Depressive disorders
Iron-deficiency anaemia (3) 4.4 4.6 (3) Diabetes mellitus
Migraine (4) 4.3 4.2 (4) Migraine
Diabetes mellitus (5) 3.7 4.0 (5) Iron-deficiency anaemia
Anxiety disorders (6) 3.6 3.6 (6) Oral conditions
Falls (7) 3.5
3.3
3.5 (7) Anxiety disorders
Oral conditions (8) 2.8 (8) Other hearing loss
Asthma (9) 2.6 2.7 (9) Falls
Other hearing loss (10) 2.5 2.7 (10)
(14) 2.0 2.2 (12) AsthmaAlzheimer’s disease
and other dementias
and other dementias
Alzheimer’s disease
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How much do we invest in health promotion and
disease prevention?
Only a small proportion of health expenditure is spent
on health promotion and disease prevention
interventions, with this share falling after the global
economic crisis
Despite an increased emphasis in policy documents and
strategic plans on health promotion and disease prevention
in European countries, levels of spending appear to be low.
For instance, it is estimated that OECD countries typically
only allocate between 2% and 4% of total health spending
to these activities [12]. Of OECD countries in the European
region, the highest expenditure on disease prevention was in
the United Kingdom, 5.2% of current health expenditure,
with only Finland and Italy also spending at least 4% per
annum on disease prevention. Moreover, between
2009/2010 and 2012/2013 on average spending fell in real
terms and still in 2014/2015 was only growing at around
2% per annum in OECD countries, a rate that is much lower
than before the onset of the global economic crisis. 
These estimates are likely to be a significant underestimate
of total spending on actions to reduce risks to health in
many countries as they do not capture all investment outside
the health sector. Countries do not measure disease
prevention and health promotion spending in a consistent
way. Some costs directly related to health actions such as the
implementation and administrative costs of new legislation
or taxes to improve health, including those related to alcohol
and tobacco consumption, as well as mass media campaigns
not funded by the health sector, are likely to be excluded
from estimates of spending. Investments by public and
private sector employers in workplace health promotion
programmes, or by ministries of sports or local government
in better access to sports facilities or green spaces, or of the
education sector in health promotion programmes, are
further examples of programmes that usually do not appear
in spending estimates. Welfare programmes that help
alleviate or reduce the risks of poverty can, for example,
reduce the risk of suicidal behaviour [13, 14], but they are
also unlikely to be included in estimates of national spending
on disease prevention and public health. 
How can we make the economic case for
 investment in health promotion and disease
 prevention?
Policy-makers want to know how to prioritize
investments for health promotion and disease
prevention, and economic evaluation can help with
these decisions
As above, the leading causes of poor health are likely to be
amenable to preventive actions. Equally, there are substantial
costs associated with avoidable poor health. It is therefore
helpful to put forward an economic case to policy-makers to
support investment in health promotion and disease
prevention. Certainly, economic arguments have been
successfully used to influence the ways in which health and
other policy-makers allocate resources to health care and
public health programmes in some country contexts. In
England, for example, since 2005 the National Institute for
Health and Care Excellence has used economic models to
inform its public health intervention guidance [15].
There are several different approaches to economic
evaluation and detailed discussions of their strengths and
weaknesses for health promotion and disease prevention are
available [16]. As with estimates of changes in the costs of
poor health, making comparisons between the results of
economic evaluations can be challenging depending on the
precise approach adopted. In essence, all involve an
assessment of effectiveness and the costs of two or more
interventions, potentially including a no-action option, as
well as changes in subsequent costs to health care systems
resulting from intervention. Evaluations may also look at
broader costs and benefits to other sectors (some of which
potentially may fund or implement relevant services) and the
economy as a whole. 
Some evaluations compare changes in costs with some topic
specific outcome measure, for example deaths avoided (a
cost-effectiveness analysis), or a metric that can be used for
all health problems such as changes in quality-adjusted life
years (QALYs) or DALYs (cost–utility analysis). Each country
will determine how much it is willing to pay for these
improved health outcomes, for instance one crude approach
might be to make this equivalent to one or more multiples
of GDP per capita in a country (a proxy threshold that has
been used by WHO in some of their economic work) [17].
Health promotion and disease prevention interventions may
also be assessed using an approach known as cost–benefit
analysis, where both costs and benefits across health and
other sectors are measured in monetary terms. If benefits are
greater than costs then the intervention is a worthwhile
investment. A similar approach to cost–benefit analysis,
return on investment analysis, compares the costs of
delivering an intervention with the costs to health and other
sectors that can be avoided as a result of intervention. While
this does not directly consider health outcomes, a positive
return on investment is usually attributable to better health
outcomes being achieved. This approach is increasingly used
as a complement to economic evaluation in making the case
for public health interventions [18, 19]. A variant of this,
social return on investment, also places a value on broader
benefits achieved through better outcomes, for example
putting a value on additional friendships gained through
health promoting actions to tackle social isolation [20].
What types of action can be taken?
Public and primary health services should be at the
heart of actions within the health system, as well as
advising and working with other sectors 
Before providing some illustrative examples on the economic
case for action, let us first look at some of the types of
actions that can be taken. Figure 3 provides an illustrative
framework of the determinants of health and potential
avenues for action to promote better health and prevent
disease or injury. It highlights underlying determinants of
health, as well as behavioural and biomedical risk factors
that affect risks to our health. It recognizes that individual
characteristics such as age, gender and genetics also
influence health. 
Figure 3 also indicates that actions can be delivered within
or outside the health system. Health systems should be at
the heart of these strategies directly delivering health
promotion and disease prevention activities, for instance to
mitigate biomedical risk factors, as well as by working with
other actors to influence implementation of effective actions
to address some of the wider determinants of health in
other sectors. 
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For example, within the health system, public and primary
health care services, including dental and optical services,
can play a vital role in primary prevention and early
intervention, through actions linked to annual health check-
ups, as well as vaccinations. Public health services can also
help ensure the provision of nutritional and dietary
supplements to high-risk segments of the population, or
advise other sectors on these issues, such as schools and
workplaces, or increase access to counselling services and
support to reduce risk of psychological and physical health
problems. They might also work more closely and be better
integrated with primary care.
Secondary prevention is more likely to be delivered by
specialist health care services, and concentrates on actions
to improve health outcomes for individuals already at high
risk of disease. These, for example, could include screening
and treatment services for cancers, while midwives and
health visitors may be on the lookout for maternal and
infant health problems. Counselling services may be
employed to address poor mental health seen in individuals
with chronic physical health problems such as arthritis or
diabetes. More generally, good management of chronic
diseases such as diabetes also reduces the risks of
complications and development of related diseases. 
The links between health and social care services vary
between countries. Sometimes they are part of the formal
health system and sometimes not, but they also have a very
important role to play in disease prevention. One example is
in assessing homes for environmental hazards, where cost-
effective actions can be taken to reduce the immediate risk
of injuries such as fall-related fractures in older people that
are a major cost to health care systems [22, 23].
Many actions are also delivered by or in partnership
with other sectors 
Many actions need to be delivered outside health systems.
Health systems can help generate knowledge on the need
for and impacts of these different actions. They can, for
example, work in partnership with ministries of finance to
evaluate the effectiveness of different potential tools
Figure 3: A framework for determinants of health and potential avenues for action 
Actions mainly delivered within health system; public, primary and specialist services, as well as social and long-term care.
Focused mainly on primary and secondary disease prevention , e.g. screening, immunization, health counselling (Table 1)
Actions often delivered in partnership with other sectors/actors; mainly actions targeted at health promotion by
influencing behaviour, e.g. taxes, regulations, health information and literacy campaigns, psychological nudges (Table 1)
Individual physical and psychlogical make-up; prenatal environment, genetics, gender, age, life-course, intergenerational influences
• Environmental factors
(e.g. school, work,
urban design, location,
air quality, home
insulation)
• Education status
• Socio-economic factors
(incl. poverty, income
inequalities, migrant
status)
• Cultural values
• Social cohesion
• Knowledge/beliefs
• Tobacco smoking
• Hazardous drinking
• Physical inactivity
• Unhealthy diets
• Substance abuse/
addictive behaviour
(e.g. gambling)
• Other risky behaviours
(e.g. sexual behaviour,
sun exposure)
• Birth weight
• Body mass index
• Blood cholesterol
• Blood pressure
• Abnormal blood lipids
• Immune status
• Noncommunicable 
physical and mental
diseases
• Communicable diseases
• Intentional injuries
• Accidental injuries
• Health care costs
• Human costs
(shorter life
expectancy,
premature mortality)
• Wider societal
costs (e.g. lost
productivity in the
workforce, lost
human capital
acquisition while at
school), including
impacts going
beyond the
individual (e.g. on
family) and
intergenerational
impacts
Individual physical and psychlogical make-up; prenatal environment, genetics, gender, age, life-course, intergenerational influences
Underlying determinants
including:
Behavioural risk factors
including:
Biomedical risk factors
including:
Disease and injury 
burden including:
Source: Adapted and augmented from [21]
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B
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available that could influence risky behaviour. One
prominent example is the use of fiscal and tax-related
measures to influence an individual’s willingness to engage
in harmful or protective activities (e.g. taxes on tobacco and
alcohol or subsidies to reduce the cost of fruit and
vegetables or increase cycling). The health system can also
provide evidence, as well as help design evaluations in areas
where evidence may be more limited, such as taxes on
sugary drinks and gambling, or subsidies for electric cars to
reduce pollution. The health system and other sectors can
work in partnership to help design effective legislation;
examples include rules on food and drink labelling,
advertising restrictions (including on social media), controls
on the display of products such as alcohol and cigarettes in
shops and regulation of the levels of salt and sugar in food.
There may be outright prohibition of some harmful risks –for
example banning smoking in workplaces or the emission of
other toxic substances into the environment. Information
and health literacy campaigns within and outside the health
system may also be employed.
Recently, attention has also turned to the use of behavioural
psychology to influence or reframe individual choices over
health promoting actions [24]. Popularized as a ‘nudging’
individual choices, these interventions can be a complement
to other measures to reduce harmful lifestyle actions. Many
of these methods are likely to be implemented outside
health systems. They have already been used to address
choices over tobacco and alcohol, and  increasingly,
examples of nudges related to physical activity and diet can
be found [25, 26]. Examples of the latter include TV
campaigns showing smoke coming out of a baby’s mouth to
emphasize the dangers of passive smoking, as seen in
Portugal. Another example is the placement of healthy food
rather than sugary snacks near the checkouts of
supermarkets in order to influence last-minute impulse
purchases [24]. Potentially, the health system can also work
with the private sector to aid in implementation; the private
sector has made use of behavioural psychology in the
proliferation in the availability of pedometers, apps and
other devices that measure physical activity to encourage
individuals to exercise and live more healthily. 
What do we know about the economic case?
Having looked at the different types of economic evaluation
methods that can be used and a broad spectrum of
potential interventions, we now provide a short overview of
some actions where there is a degree of consensus that they
are likely to either be cost saving or highly cost-effective in
different country contexts (See Box 1). 
Box 1: Defining cost saving and cost-effective interventions
In this brief, cost saving interventions are those that have both
better outcomes and lower costs than the usual intervention, while
highly cost-effective actions have an additional cost per quality
adjusted life year (QALY) gained or DALY averted at less than country
specific GDP per capita level. Some studies instead report cost-benefit
analyses or return on investment analyses; studies that have a
positive return on investment, where the monetary value of
benefits outweighs the costs of action are also included. These are
also considered to be cost saving.
There are many examples of interventions that are
highly cost-effective or even save costs
The summary takes as its starting point evidence collated in
reviews of the economic case for action. This includes
reviews of work undertaken in the WHO European Region,
as well as evidence from other high-, middle- and low-
income country contexts around the world, including the
WHO’s ‘Best Buys’ document which identifies interventions
that would be considered cost-effective in low- and middle-
income country contexts [27-33]. This review also draws on
detailed economic evidence and reviews commissioned by
the National Institute for Health and Care Excellence in
England over the last 13 years to inform their public health
guidance [15], and recent return on investment work
commissioned by Public Health England [34]. It should be
stressed that these examples (summarized in Table 1) are not
an exhaustive list of all cost savings and cost-effective
actions. Where possible, examples from the WHO European
Region context are provided, but it should again be stressed
that these findings are context specific and cannot simply be
generalized to different country settings. It does not focus
on actions where benefits in individual countries cannot be
identified; for instance readers may also be interested in
recent modelling work looking at the return on investment
in public health interventions solely for low- and middle-
income countries as a whole rather than individually, most of
whom are outside of the WHO European Region [35].
(1) Actions delivered within health care systems
Many preventive actions can be delivered within health care
systems and some examples are set out here. In addition, we
note strategies that involve a combination of actions taken
within and beyond the health care system to promote
health, for example to reduce harmful drinking. Some
strategies have immediate benefits to the health care
system, while some take a number of years to realize their
full benefits.
Brief advice on physical activity given in primary care
settings to at-risk groups in high-income settings can be
highly cost-effective [36]. This is particularly the case when
mental as well as physical health benefits (coronary heart
disease, stroke and type 2 diabetes) are considered [37]. One
example of this concerns investment in collaborative care in
primary care to deal with psychological distress and the risk
of depression and anxiety disorders that has been associated
with diabetes and cardiovascular diseases [18]. From a
societal perspective after just two years there was a positive
return on investment of $1.52 for every $1 invested in the
United Kingdom’s context, although most of these benefits
were gained outside the health and social care sector.
Lifestyle interventions and/or drug therapy (secondary
prevention) for at-risk individuals with impaired glucose
intolerance have also been shown to be highly cost-effective
or cost saving in some country contexts [38-40], but the
magnitude of these costs and benefits is difficult to
determine because of differences in study design [41].
Indeed in some contexts, for example in Kyrgyzstan,
modelling suggests drug therapy is not cost-effective [42].
Another illustrative example concerns screening
programmes. Screening for hazardous drinking followed by
brief intervention within the health care system has been
found to be cost saving in 14 EU countries, and highly cost-
effective in another 10; however, these interventions were
not cost-effective in four countries [43]. Another example is
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Table 1: Illustrative examples of cost saving and highly cost-effective actions to promote health
and prevent disease 
HIGHLY COST-EFFECTIVE: COST SAVING:
• Brief physician advice for regular physical activity (UK)
• Screening programme for older women at high risk of
hip fractures (UK)
• Collaborative care for mental health delivered in
primary care to people with diabetes and/or
cardiovascular disease (UK)
• Screening and brief intervention for hazardous
drinking (EU28)*
• Universal hepatitis B vaccination (Italy)
Behavioural risk factors:
Tobacco smoking
• Taxation to increase price of cigarettes (Netherlands)
• Implementing a price increase for cigarettes (World
Bank Europe and Central Asia Region)
• Mass media campaigns to encourage quitting (UK)
• Peer school tobacco prevention programmes (UK)
Hazardous drinking
• Drink driving legislation and enforcement
WHO Euro C Region)**
• Reduced access to alcohol in shops
(WHO Euro C Region)
• Increase in excise taxation or improved tax
enforcement (WHO Euro C Region)
• Combination (brief advice, random breath-testing,
reduced access, advertising ban, plus increased tax
and enforcement) (WHO Euro C Region)
Physical inactivity
• Dedicated cycle lanes (New York, USA)
• Mass media campaign to promote physical activity
(Australia)
• Mass media health promotion campaign 
UK-England, Russian Federation)
Unhealthy diets
• Mass media health promotion campaign 
(UK-England, Russia)
Other determinants and risk factors:
• School-based tobacco prevention programmes
(Germany)
• Increase in taxation or advertising bans or reduced
retail opening hours (Denmark)
• Minimum unit price (Ireland)
• Pedometers as a motivational tool for activity
(Australia)
• Subsidies on fruit and vegetables and tax increases on high fat
foods (UK-England, Russian Federation)
• Tax on sugary drinks (USA)
• Food reformulation to reduce salt content (UK-England)
• Mandatory labelling of salt content (UK-England)
• Food reformulation to ban trans-fatty acids (UK England & Wales)
• Nationwide salt policy package*** (Kyrgyzstan)
• Public awareness campaigning on physical activity (Belarus)
• Increased enforcement of speeding, drink-driving and seat
belt laws (Norway)
• Home hazard assessment for fall prevention (UK)
• Programme to promote social, emotional and behavioural
development in areas of high risk for poor childhood
development (Canada)
• Parenting programmes to prevent long-term behavioural
problems in at-risk children (UK)
• Provision of universal workplace physical and mental health
promotion programmes (UK)
• Provision of universal workplace mental well-being
programmes (EU countries)
Sources: Based on Tables in the Appendix.
Notes:*Cost saving in 14 countries, cost effective in 10, not cost effective in 4 (Bulgaria, Croatia, Estonia, Romania). **WHO Euro C Region = Belarus, Estonia,
Hungary, Kazakhstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, Ukraine. ***Surveillance of salt consumption patterns, education and
awareness programme and salt-reduction strategies in community eating spaces (including schools, workplaces, hospitals).
(1) Actions mainly delivered within health system
(2) Actions often delivered in partnership with other sectors / actors
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bone mineral density measurement. For instance, recent trial
data in England were used to look at the cost-effectiveness
of screening high-risk older women on bone mineral density
measurement and 10-year risk of hip fracture in order to
help prevent fractures [44]. Over five years, the cost per
QALY gained was $4111, a value considered highly cost-
effective in a United Kingdom’s context. The analysis is also
conservative as it does not take into account the social care
and long-term care costs averted. 
Many immunization programmes also provide positive
returns on investment, for example a retrospective analysis
looking at the first 20 years of a hepatitis B immunization
programme for infants in Italy found that it more than
covered its costs from a health sector perspective within this
time-period; the authors then modelled the long-term
impacts over a further 49 years. This showed that costs
averted by the health care system would be almost three
times greater than the costs of the programme [45].
(2) Actions delivered in partnership with other sectors/actors
There is also an economic case for actions outside health
systems and in this brief we now provide some illustrative
examples covering tobacco and alcohol consumption,
physical activity and diet, early years interventions for
children, workplace health promotion and road traffic
injuries.
Tobacco control
Evidence-based tobacco control policies, consistent with the
WHO Framework Convention on Tobacco Control (FCTC)
which includes multisectoral demand and supply side
measures [46, 47], can be highly cost-effective, both in the
WHO European Region and globally [10, 48, 49]. Articles 6
to 14 of the FCTC cover measures relating to the reduction
of demand for tobacco. Examples of actions include
taxation and/or price increases; economic analyses
demonstrate that the costs of implementing such measures
are more than outweighed by the long-term benefits from
the reduction in smoking-related disease and premature
death that arise from a reduction in tobacco consumption
[49, 50]. Another example of this multi-pronged approach,
mass media advertising campaigns, can also be cost-
effective [51, 52]. Another example is action to ensure
protection from exposure to tobacco smoke, such as in
indoor workplaces. Smoke-free workplaces have been
shown to have a positive return on investment even from
the narrow perspective of businesses; this is further
strengthened when considering benefits to the health sector
and society [52]. The FCTC also notes that measures to
reduce tobacco use include effective and appropriate
training on tobacco control addressed at specific key
individuals, which can include educators, while the WHO
Health Promoting Schools: a Framework for Action notes the
importance of policies in schools to prevent tobacco use
[53]. Potentially effective actions that could be part of a
multisectoral approach to tobacco control include school-
based programmes delivered by teachers and peers to
raise awareness of the dangers of smoking and thus help to
reduce long-term smoking uptake [54-56] and generate
positive long-term economic benefits [57, 58].
Hazardous drinking
When looking at the benefits of reducing hazardous
drinking levels, many economic models place a monetary
value on immediate benefits beyond health systems such as
reduced violence and other crime, workplace accidents,
absenteeism and road traffic delays. There is also an
immediate reduction in hospitalizations and other health
care service use associated with these events. Preventive
actions outside the health system are therefore usually cited
as being highly cost-effective or cost saving. They include
the enforcement of price rises, as well as limiting retail
access to alcohol and limiting advertising [59, 60]. The
introduction of a minimum price per unit of alcohol may
also be cost-effective in some country contexts. In Ireland, if
a $1.15 minimum price was set, then modelling suggests
that within a year costs to the health care system of
$6.6 million could be avoided. There would also be averted
crime-related costs of $6.3 million and $13.9 million in work
absenteeism. Over 20 years, total costs avoided would be in
excess of $524 million, increasing to $1.51 billion if a
monetary value is also placed on quality of life gains [61].
Other measures that are likely to be highly cost-effective
include drink–driving legislation and measures such as
random breath-testing campaigns [59]. A package
combining measures within the health care system such as
brief advice, alongside some measures delivered in other
sectors, suggests that this will generate sufficient additional
health benefits and remain highly cost-effective in the WHO
European Region, despite higher costs [62].
Physical activity and diet
Another area where partnerships with a range of actors in
different sectors are helpful concerns the promotion of
physical activity and healthy diets. Again most of the
economic analyses are modelling studies, many from outside
the WHO European Region; promising interventions include
mass media campaigns to encourage physical activity; they
can be cost-effective and sometimes cost saving in some
contexts, such as shown in economic modelling work in
Belarus [28, 63, 64]. Behaviour change interventions that
motivate individuals to take part in physical activity can also
be cost-effective. Over a lifetime measures such as the use
of pedometers [28] and changes to the built
environment that encourage more ‘active travel’, for
example walking or cycling, have been modelled to be cost-
effective in some settings [65]; but this can be very
context/location specific [66], thus limiting generalizability.
Actions to influence diet include taxation on unhealthy
food and drinks. These taxes tend to be cost saving over
very long time periods in modelling studies because of
favourable reductions in conditions such as cardiovascular
diseases, diabetes and stroke, as well as improvements in
oral health [67-69]. However, there may be potential adverse
effects of taxes on those with low incomes who face
additional barriers to behaviour change and thus are left
with less money for other uses; subsidies targeting healthy
food or disadvantaged consumers may help address this
concern [70]. Even if individuals do change their dietary
habits, the level of health benefits gained will also partly
depend on what they eat or drink instead. 
Another limitation here is that practical experience
implementing these taxes remains limited, although some
appear to have changed consumer behaviours. For instance,
in Mexico a sustained 7.6% reduction in the consumption of
taxed sugary drinks has been seen in the two years after the
tax was introduced [71]. The recent levy on sugary drinks in
the United Kingdom appears, initially at least, to have
sufficiently incentivized many in the drinks industry to
reduce the sugar content of their products to fall below the
limit at which the levy would apply [72]. In any event, a
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combination of actions, for example involving product
reformulation and information campaigns, may be
preferable [73].
Increasingly sophisticated epidemiological models are
available that can specifically look at the association
between a change in health behaviours and impacts on
future health problems, such as cardiovascular diseases and
diabetes. These include a number of economic analyses
informed by epidemiological analyses that potentially
suggest product reformulation to reduce the level of salt and
trans-fats in processed food can be highly cost-effective or
cost saving [74, 75] and lead to significant improvements in
health and averted mortality. Strategies that mandate or
strongly encourage product reformulation, sometimes in
combination with other strategies such as labelling, media
campaigns and restrictions on fat levels in restaurant
food, can also be cost saving [68, 75-77]. Combined diet
and physical activity promotion programmes, involving at
least two contacts with service providers, have mainly been
shown to be highly cost-effective, but not cost saving [78]. A
economic model with a combined strategy involving better
salt surveillance, an education campaign and measures to
encourage reduced consumption of salt in communal eating
areas was estimated to generate a twelvefold return on
investment after 15 years in Kyrgyzstan [42].
Other areas for action
There are many different risks to health where an economic
case for investment in disease prevention and health
promotion can be made for which there is insufficient space
in this brief. For instance, collaboration between health
and other sectors to promote physical and mental
well-being in childhood is economically very sound. This
includes taking action during the perinatal period to support
mothers and their infants, as well as investing in emotional
resilience and health literacy, parenting programmes
(particularly targeted at high-risk groups) and anti-bullying
measures [79]. There is, for example, long-term evidence
from a number of studies indicating that actions to
promote better mental resilience and enhance
educational support are cost saving when impacts on
sectors other than health are considered, as for instance
illustrated by social, emotional and educational development
programmes in Canada and the United Kingdom [80, 81].
Health systems can also benefit by collaborating with
occupational health services and workplaces,
particularly small- and medium-sized workplaces that may
have limited occupational health services to promote
physical and mental well-being in the workplace. Evaluations
generally show a positive return on investment both to
employers and health care systems [82, 83]. There is also a
strong economic case for the health sector to continue to
work with transport and justice sectors, as well as with
the automobile industry, for enhanced enforcement of
safety measures such as traffic calming and speed reduction
measures, increased use of seat belts and more safety
features installed into vehicles, all of which can be cost
saving [84]. 
Interpreting results
This brief has illustrative examples of many different health
promotion and disease prevention actions found to be cost-
effective or cost saving. Recent reviews generally conclude
that many investments in health promotion and disease
prevention represent good value for money, helping to reduce
some avoidable immediate and downstream demands for
health care treatments [27, 29]. Return on investment
methodologies are increasingly used, with one recent example
being ongoing work at global level to identify the economic
case for addressing some risk factors for poor health in terms
of the impacts on the future costs of specific health problems
such as cardiovascular diseases [19].
Policy-makers should be careful when interpreting
results of evaluations and carefully examine the
assumptions made
Nonetheless, the multiplicity of methods used means that
policy-makers should be careful in the way that they
interpret the results of these and other economic
evaluations. Economic evaluations of the same intervention
in the same country context could lead to very different
conclusions depending on the method used. This is not just
because of the difference in outcome measurement; many
other factors also play a role. 
One of the most important is the perspective adopted in
evaluation. A narrow focus on costs and impacts on the
health system alone, particularly when successful
implementation requires funding and other support outside
the health sector, for example in workplaces, may be
unhelpful. It also ignores broader economic benefits of
better health, such as greater levels of participation in
employment or education. While many disease prevention
and health promotion interventions represent good value
from a health system perspective alone, it is important to
recognize that interventions may generate more benefits
outside the health system.  For instance, a key driver of
actions delivered within or around school settings, such as
many social and emotional literacy and resilience
programmes for children and young people, impacts on
educational outcomes and the school environment,
including teacher health [41].
A second key issue when looking at the economic case for
investment in health promotion and disease prevention is the
time horizon over which benefits and costs are incurred and
how this is dealt with in economic evaluation. Unlike many
interventions to treat health problems that usually have fairly
immediate impacts, the benefits of many health promotion
and disease prevention interventions may take a number of
years to be generated. For instance, investing in measures
early in life to reduce the risk of childhood obesity may lead to
health benefits many decades later, including a reduced risk of
dementia in old age [3]. The same can be said of many
actions to reduce the uptake and continued use of tobacco,
although there are exceptions such as the immediate benefits
to the unborn child of women who stop smoking during
pregnancy. This long-term time horizon before impact is
achieved may be a barrier to investment for some policy-
makers more concerned with shorter electoral cycles.
A further related issue concerns the use of discounting in
economic evaluation. Traditionally, benefits (and costs)
incurred more than one year in the future are discounted; in
the United Kingdom, for example, they are currently
discounted at a rate of 3.5% per annum. This means that
benefits many years in the future will appear to have only a
small fraction of their value had they occurred in the current
year. This means that the cost-effectiveness of disease
prevention/health promotion interventions can appear to be
less favourable than investment in immediate health care
treatments. Yet many individuals would consider good
health in the future to be of great value.
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Given that the long time horizon for many interventions is
beyond that seen in most randomized-control trials, there is
a reliance on economic models to estimate the long-term
costs and benefits of health promotion interventions, in
some cases looking at impacts over many decades. There
may be considerable uncertainty over the sustainability of
health benefits over time, and therefore it is important that
detailed sensitivity analyses are undertaken which look at
potential costs and benefits under very conservative and not
just optimistic scenarios on the sustainability, for example, of
behaviour change. 
Models also need to take account of the consequences of
behaviour change; for instance much of the work on the
case for investing in taxes on unhealthy food and drinks
partly depend on modelling assumptions not only on
whether individuals will reduce their consumption of sugary
drinks but also what they will switch to. Some alternative
options such as natural fruit juices or full fat milk potentially
are less beneficial in terms of risks of obesity or poor oral
health compared to switching to water. If consumers simply
spend more of their disposable incomes on unhealthy food
and drinks, then they will have even fewer resources left for
other goods and activities, potentially further harming their
health. Models therefore need to be transparent on the key
assumptions that they make. 
Potential ‘best buys’ in one country may not always be
cost-effective in another: health system and broader
country institutional and cultural contexts are very
important
Health system and broader country institutional and cultural
contexts always have an impact on effectiveness, cost-
effectiveness and likely implementation. Interventions that
have been proven to be potential ‘best buys’ in one country
may not always be cost-effective in another. For instance, in
28 separate analyses screening and brief interventions in
health care systems to reduce hazardous drinking in Europe
were found to be cost saving in 14 countries, cost-effective
in 10 more, but not cost-effective in four countries [43]. 
This needs to be considered by decision-makers when
assessing whether or not to implement a programme or
policy that has been shown to be cost-effective in one or
more different contexts. Take for example a hypothetical
legislative measure to reduce access to harmful products.
The effectiveness of legislation depends, in part, on cultural
attitudes towards laws, as well as how well these laws are
likely to be enforced and the severity of penalties for any
infringement. Countries can also learn from failure, as well
as success. This could include learning from experiences
where resources might have been allocated to interventions
with a weak evidence base on effectiveness, as well as
identifying poor implementation of potentially cost-effective
interventions. 
A country specific modelling analysis, as well as pilot study,
can help assess the likelihood that this action can be
delivered adequately and represent a good use of resources.
Such a detailed economic modelling study in Kyrgyzstan, for
example, found no evidence to support investment in
provision of drug therapy, including glycaemic control for
diabetes, and counselling as a way of reducing
cardiovascular risk in at-risk population groups; the costs of
the programme to the health care system far outweighed
societal benefits achieved [42]. In contrast, the model
estimated positive returns on investment on measures
delivered outside the health care system to reduce salt and
tobacco intake and promote physical activity. Another
example of this type comes from modelling work
undertaken in Belarus [64]. As in Kyrgyzstan this modelling
analysis predicted substantive returns within 15 years on salt
reduction, physical activity, tobacco and alcohol control. In
contrast, cardiovascular diseases and diabetes clinical
interventions did not generate positive long-term returns on
investment.
The results of economic analysis should also not be
considered in isolation; the costs of future implementation,
including the costs of any workforce expansion and scaling
up of services also need to be considered. Many economic
evaluations also do not consider equity implications; health
promoting actions might inadvertently widen health
inequalities if those that benefit most are those least in need
of support in maintaining their health. Again it is important
to consider equity concerns when looking at the results of
economic evaluations – studies may be able to separately
report impacts on different population subgroups or
consider the economic case for investing more in actions to
better engage with those who could benefit most from
health promotion and disease prevention actions [85]. Much
of the burden of YLDs, such as for poor mental and
musculoskeletal health, has been skewed towards low-
income population groups – disease prevention and health
promotion actions might therefore explicitly wish to focus
more resources and efforts on these groups in line with the
concept of proportionate universalism [86]. 
Making it happen: using economic evidence to
help overcome barriers to implementation
In this brief we show there is a sound economic case for
investing in measures to promote health and prevent disease
and injury, although an imbalance in the existing evidence
base remains, with most of the evidence coming from a few
countries in North America, Australasia and western Europe
with a long tradition in health economic evaluation. Yet,
despite this ever growing body of evidence we have seen
that identifiable spending on health promotion and disease
prevention within health systems remains very low. Those
controlling the purse strings within health systems appear
reluctant to allocate more of their limited resources to these
activities. Even in relatively well-resourced systems, for
instance in England, funds intended for public health have
been diverted to other activities [87].
Tables 2a and 2b summarize some of the different barriers
to investment and implementation that have been identified
and how they can be overcome [88, 89]. These issues are
further discussed in this section of the brief.
There is a need to challenge misconceptions about the
value of investing in health promotion and disease
prevention
This is not just about more effective communication of the
strength of the effectiveness and economic evidence, but
also about challenging the view that these interventions,
unlike health care treatments, are only worth implementing
if they are shown to save money. In other words, that
interventions always have to be cost saving from a health
system perspective rather than simply being cost-effective,
with better outcomes but at a cost that is considered worth
paying. The view that the benefits of disease prevention are
overstated because the long-term additional costs of living
longer are not included also needs to be challenged [89].
Not only is this unfair, as this is rarely considered when
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looking at the value of treatment in the health care system,
but interventions that promote health and potentially extend
life may actually result in a compression of morbidity,
reducing demands for resources, leading to longer, healthier
lives, with a shorter period of poor health near the end of
life [90]. It is far from certain that extending life leads to
greater use of health services. Better continuing training in
the health care workforce may also help assure some
professionals that they could have a role to play as part of
health promotion and public health services as well as in
health care services; an example of this are nurses who
undertake additional training to work as public health
professionals. 
Identifying short- as well as long-term impacts
Many of the illustrative interventions in this brief may take
many years to realize their full economic and health benefits.
Clearly when the outcomes of investment may not be seen
for such a long time elected politicians may understandably
not place health promotion and disease prevention at the
top of their political priorities. Equally, some health care
providers may be reluctant to invest and not see benefits for
a very long time when they have so many pressing issues to
deal with. In an ideal world building a political consensus
around health policy might be a way for countries to ensure
sufficient investment in long-term measures, but this may be
difficult to establish and sustain.
A more practical measure may be to identify cost-effective
short-term investments, for instance home hazard
assessment for falls, avoidance of harm to the unborn child
through smoking and alcohol cessation programmes during
pregnancy, psychological interventions to protect the mental
health of people living with chronic diseases, and adherence
to safer sex practices. Short-term wins may help create the
space and greater acceptance of other investments that may
take many years to reach fruition. The benefits to future
generations of children and grandchildren of health gains
may also help promote public support. 
Stimulating and facilitating intersectoral activity
Some actions to promote and protect health are delivered
outside the health system. Other sectors may have little
interest in better health as a policy objective. Fragmented
funding and accountability structures, mutual mistrust and a
lack of legal and regulatory frameworks to stimulate
intersectoral partnerships between health system actors are
among some of the obstacles to intersectoral activity.
Another practical challenge concerns what has been
described as ‘diagonal accounting’, where one sector may
shoulder the financial responsibility for delivering a service,
while another sector is perceived to make most of the gains
(and avert costs) at some future point in time [88]. 
It is important therefore to highlight ‘win-win’ situations
where health and other sectors benefit from investment in
disease prevention. However, health systems need to be
much more effective in speaking the language of other
sectors when trying to leverage funds and/or create
conditions for partnership working. For instance,
emphasizing improvements in educational attainment,
classroom atmosphere and teacher sickness absence rates
from school-based mental health intervention can act as a
catalyst for their implementation by the education sector
[91]. Changes to taxation may also be attractive if, as can be
the case, they are easy to implement. Where tax
infrastructures already exist, the marginal costs of
implementing changes to taxation levels may be low.
Taxation measures can be made even more attractive if any
revenues raised (even though revenue generation is not their
primary purpose) are earmarked for reinvestment into the
health system or external health promoting infrastructures,
such as sports facilities and green spaces. 
In England many health promotion and public health actions
fall under the responsibility of local councils. Public Health
England (a national agency that provides government, local
government, the National Health Service (NHS), Parliament,
industry and the public with evidence-based professional,
scientific expertise and support) commissioned a number of
different return on investment tools to aid decision-making,
including by local councils and other non-NHS organizations
(Box 2) [34].
Box 2: Use of return on investment tools to aid local decision
making in England
Public Health England has commissioned health economists to
develop a number of return on investment tools. These are intended
to bring together in a single place the best available evidence on
costs, savings and health benefits, for a range of interventions for
different health concerns, in order to aid in decision-making on
disease prevention and health promotion by local government and
health services.
So far 10 models have been published looking at:
• Colorectal cancer
• NHS Diabetes Prevention Programme
• End of life care
• Weight management
• Oral health in preschool children
• Mental health promotion
• Musculoskeletal conditions
• Movement into employment
• Falls prevention
• Best Start in Life
Each model calculates the return on investment for different
interventions to selected different sectors over different time frames.
For example, the falls prevention model reports a return on
investment to health and social care services of £3.17 for every £1
invested in home assessment and modification services, while in the
mental health promotion tool, investment in debt advice and
management services has a return on investment of £2.60 to health,
legal services and employers for every £1 invested.
Sources: [18, 23, 34]
Other approaches to support intersectoral activity include
mechanisms and regulatory structures to allow different
organizations across sectors to share resources and
responsibilities around health promotion and disease
prevention goals, as well as the creation of dedicated health
promotion and public health bodies that have a remit for
working across sectors [92, 93]. Simply co-locating relevant
health and other sector services can also help build trust and
increase the likelihood of shared goals being set [94].
Effective communication helps
Better communication is another element for facilitating
implementation. This means investing in specialist
communication capacity where individuals have skills in
communicating research needs and outputs and who also
are comfortable in decision-making environments. 
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Decision-makers have to contend with many different voices
arguing for different ways in which resources can be used;
specialist communication, research and public health skills
are needed to help separate robust sources of evidence from
other materials and distil this into succinct messages to aid
decision-making. These specialist professionals can also help
liaise with researchers, including economists, in order to
commission research that is most practical and useful to
health systems, but also realistic to achieve. It has also been
argued that population health actions are at a disadvantage
compared to health care treatments as they often do not
have ‘identifiable victims’ and thus have suggested that
social marketing and other strategies should be used to give
a ‘human face’ to the potential beneficiaries of public health
interventions [89].
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Table 2a: Examples of barriers to investing in health promotion and disease prevention and how
they can be overcome
BARRIERS TO INVESTING POTENTIAL SOLUTIONS
Perceptions and expectations of some policy
makers and health care service providers, for example:
• Perception that the evidence base on the effectiveness
of health promotion and disease prevention
interventions is weaker than that for health care
treatments
• Perception that investment in disease prevention
means there will be fewer resources available for
health care treatment
• Fears that greater investment in health promotion and
disease prevention means divesting from health care
services leading to job losses
• Belief that, in the long run, disease prevention costs
more than other health spending because individuals
live longer and cost the health system more in the
long run
• Expectation that public health interventions only
represent good investments if they save money
Continued efforts to change perceptions and beliefs
about health promotion / disease prevention
interventions, for example:
• Communicate in clear everyday language that
evaluations show disease prevention and health
promotion are effective
• Demonstrate that better health potentially can help to
free up resources for health care services by reducing
avoidable health problems
• Short-term positive returns on investment are
achievable and can help free up resources for health
care systems by reducing some avoidable service use;
workforce can also be retrained to work more in public
health, e.g. more nurses moving into public health
• Treatment interventions also have the potential to
extend life; extra life years have value; interventions that
extend life can also result in compression of morbidity,
with people living longer, healthier lives, with a shorter
period of poor health near the end of life
• While some health promotion / disease prevention
interventions are cost saving, in general, health
promotion / disease prevention should not be required
to meet higher standards of economic effectiveness
than health care services
Timeframe
• Longer timeframes to impact compared to clinical
interventions that often go beyond the electoral cycles
of politicians
• Conventional use of discounting in economic analysis
means that benefits appear less appealing the further
into the future they occur; in contrast many health
care treatments have more immediate benefits that
are not affected as much by discounting
• Establish cross-party dialogue and seek to establish
cross-party consensus on very long-term public health
strategies and goals
• Identify interventions with short-term benefits (e.g.
avoiding smoking in pregnancy, fall prevention, infant
immunization, contraception), as well as interventions
with mid- to long-term benefits
• Identify intermediate shorter-term health benefits, e.g.
reduced levels of smoking
• Show annual levels of benefit where feasible from
delays as well as avoidance of morbidity and mortality
• Report undiscounted as well as discounted costs and
benefits
• Highlight value of intergenerational benefits linked to
better health; this may encourage the public to
recognize potential benefits for their own future health
and that of their children and grandchildren, thus
personalizing the benefits
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Table 2b: Examples of barriers to investing in health promotion and disease prevention and how
they can be overcome
BARRIERS TO INVESTING POTENTIAL SOLUTIONS
Intersectoral activities
• Actions to promote and protect health should be
delivered outside the health system; these other
sectors have little interest in better health as a policy
objective
• Fragmented funding structures for intersectoral
activities
• Lack of past collaboration / mistrust create barriers to
intersectoral action
• Financial risks and incentives are not shared equally
across sectors; a situation of ‘diagonal accounting’
can arise where one sector may shoulder the financial
responsibility for delivering a service at one time point,
while another sector is perceived to make most of the
gains (and avert costs) at some future point in time
• Be prepared to identify and emphasize non-health
sector specific benefits associated with health
promotion and disease prevention when making a case
for investment outside the health system rather than
health benefits
• Identify potential shared objectives and goals and
highlight ‘win-win’ situations where health and many
other sectors (not just ministries of finance) benefit
from investment in disease prevention
• Co-locate relevant health and other sectors to help
establish working relationships and trust
• Introduce mechanisms and regulatory structures to
mandate or encourage different organizations across
sectors to share resources and responsibilities around
health promotion and disease prevention goals
• Create dedicated health promotion and public health
bodies and funds explicitly focused on implementing
working across sectors
Population interventions are impersonal and
less attractive
• Lack of ‘identifiable victims’: whereas clinical medicine
typically deals with identifiable people (patients),
beneficiaries of public health measures are generally
unknown and not yet ill
• Combine public health with social marketing
approaches to give a human face to the potential
beneficiaries of public health interventions
• Instead of focusing on the large number of unidentified
people who could benefit from public health
interventions, create an image of a single individual
who could benefit, and with whom decision-makers
can identify
Communication and complexity
• Policy makers have to contend with a wide range of
influences including special interest groups, industry
and the general public each with their own
perspectives; many of these influences may not
prioritizes health promotion and disease prevention
over treatments
• Complexity of policy and funding decisions: evidence
is not the only driver of policy and funding decisions;
competing influences, including organizational,
political and strategic factors; financial and resource
constraints; personal experience; common sense;
expert opinion; stakeholder and public pressure;
community views and local competition, can restrict
the use of research evidence in health-related
decision-making
• Strategies are required to facilitate iterative dialogue
between researchers and decision makers
• The environment within which decision makers work, in
terms of structure and rewards, should be adapted to
encourage the use of research evidence
• Invest in specialist communication capacity where
individuals have skills in communicating research needs
and outputs and also are comfortable in policy-making
environments
Inside Pages TALLINN_02_McDaid_PRINT.qxp_Policy_brief_A4  23/08/2018  12:19  Page 22
23
Using economic evidence to help make the case for investing in health promotion and disease prevention
Conclusions
Spending on disease prevention and health promotion
 appears to be low, despite evidence on the effectiveness of
many different interventions. The challenge is to focus on
how best to help translate evidence-based knowledge into
routine everyday practice across the WHO European Region.
Economic evidence can be used as part of the policy-making
process to help increase investment within and outside
health systems. There is a strong economic case for invest-
ment in the promotion of better health and prevention of
disease and injury; illustrative examples of cost-effective and
sometimes cost saving actions in different country contexts
have been highlighted. 
However, there are still many gaps in the evidence base,
including much less information on the economic case for
action in the eastern part of the WHO European Region and
a need for more information on interventions with short-
term as well as long-term impacts. There is a lack of
evidence on the value of investing in behavioural psychology
influenced interventions that have had raised profiles in
recent years. It is also the case that much of the existing
literature does not directly look at the equity implications of
interventions; this is needed to help reduce the risk of
inadvertently widening health inequalities by failing to reach
those segments of the population in most need.
However, simply increasing the volume of economic
evidence is unlikely to be sufficient to make a dramatic
impact on overall levels of investment. This requires much
more attention to be placed on the way in which evidence
can be translated into practice. Ministries of health as well as
ministries of finance can play pivotal roles in incentivizing
different actors within and outside the health system to
invest in disease prevention. Some of this is about
implementation and political science, but there are
important contributions that economics can also make.
These include devoting more efforts to the generation of
return on investment analyses that place as much (if not
more) emphasis on the value of non-health benefits to
sectors that the health system wishes to influence or partner
with. This needs to go beyond a focus solely on ministries of
finance but should consider many more sectors, such as
housing, education, social welfare, justice and transport.
Financial and other economic incentives, contracts and other
regulatory arrangements can also be used to stimulate new
partnerships between the health system and other sectors.
The same approach might also be used to stimulate even
more partnership working between public health
professionals and other actors within health systems.
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Appendix
Illustrative examples of cost saving and cost effective
actions to promote health and prevent disease 
All values in the tables below are in purchasing power parity
(PPP) adjusted 2016 international dollars.
Table A1: Examples of actions delivered within the health sector
Intervention Country Context specific examplesof return on investment
Perspective / Time
 period Conclusion
Brief physician advice for
regular physical  activity
UK [37]
Cost per QALY gained of
$2715 
Health/Lifetime Highly cost effective
Collaborative care for
 mental health delivered in
primary care to people with
diabetes and/or
 cardiovascular disease
UK [18]
Positive Return on Investment
$1.52 for every $1 invested in
programme
Health, productivity/
2 years
Cost saving
Screening and brief
 intervention for hazardous
drinking
EU 28
Countries
[43]
Cost per QALY gained ranging
from cost saving in 
14 countries to $42 569
Health care/10 years
Cost saving 
14 countries, Cost
 effective in 10, not
cost effective in
four – Bulgaria, 
Croatia, Estonia, 
Romania
Universal hepatitis B 
vaccination
Italy [45]
Return on Investment  Analysis.
$2.78 for every 
$1 invested from health system
perspective.  Programme also
breaks even within 20 years
Health care and societal/
68 years
Cost saving
Screening programme for
older women at high risk of
hip fractures
UK [44]
Cost per QALY gained of 
$4111
Health system/5 years Highly cost effective
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Table A2: Examples of actions to address smoking
Intervention Country Context specific examplesof return on investment
Perspective / Time
 period Conclusion
Taxation to increase price
by €0.22 per pack of 
19 cigarettes
Netherlands
[50]
$6539 per QALY gained Health care/75 years Highly cost effective
Implementing a 33% price
increase
World Bank
Europe &
Central Asia
Region [10]
Between $5 and $55 per DALY
saved gained
Health care/50 years Highly cost effective
Mass media campaigns to
encourage quitting
UK 
(England)
[51]
$844 per life year gained Health care/Lifetime Highly cost effective
School-based tobacco
 prevention programmes
Germany
[57]
Benefit : Cost Ratio 3.6:1 
Health care & productivity
costs/Lifetime
Positive return on
 investment
School-based tobacco
 prevention programmes
England [58] 
$2 477 per additional student
not smoking
Health care & local
 government/2 years 
Cost-effective in short
term and highly  
cost-effective if long-
term benefits also
considered
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Table A3: Examples of actions to address hazardous drinking
Intervention Country Context specific examplesof return on investment
Perspective / Time
 period Conclusion
Drink driving legislation
and enforcement
WHO Euro C
Region [59]*
Cost per DALY saved $941 Health care/Lifetime
Highly cost 
effective**
Reduced access to alcohol
in shops 
WHO Euro C
Region [59]*
Cost per DALY saved $683 Health care/Lifetime Highly cost effective
Excise taxation increased by
20% or improved tax
 enforcement by 20%
WHO Euro C
Region [59]*
Cost per DALY saved $458 and
$600
Health care/Lifetime Highly cost effective
30% increase in taxation or
advertising bans or reduced
retail opening hours 
Denmark [60]
All cost saving: nationwide at
least $14.05 million lower costs
and 1911 DALYs saved
Health care/Lifetime Cost saving
Minimum unit price be-
tween of €0.4 and €1.20 Ireland [61]
Nationwide between 8 and
2561 QALYs gained and costs
avoided between $11.9 and
$3533million
Health, crime, work, 
societal/20 years
Cost saving
Combination (brief advice,
random breath-testing,
 reduced access, advertising
ban, plus increased tax (by
50%) and its enforcement
(50% less unrecorded
 consumption)
WHO Euro C
Region [59]*
Cost per DALY saved $909 Health care/Lifetime Highly cost effective
Notes: * Covers Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of Moldova, Russian Federation, Ukraine. ** When broader perspective is
taken, including impacts on road management and value of life lost, intervention is shown to be cost saving.
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Table A4: Examples of actions to address physical inactivity and unhealthy diets 
Intervention Country Context specific examples ofreturn on investment
Perspective / Time
 period Conclusion
Dedicated cycle lanes in
New York city
USA [65] Cost per QALY gained of $1310
Health, transport/
Lifetime
Highly cost effective
Pedometers as a motiva-
tional tool for activity
Australia [95]
20 000 DALYs averted; 
$415 million saved 
Health/Lifetime Cost saving
Mass media health promo-
tion campaign
UK (England),
Russian Fed-
eration [67]
Cost per DALY averted $31 208
& $15 559 
Health/20 years Highly cost effective
Mass media  campaign to
promote physical activity
Australia [95]
23 000 DALYs averted; 
$ 425 million saved
Health/Lifetime Cost saving
Subsidies on fruit &
 vegetables & tax increases
on high fat foods
UK (England),
Russian Fed-
eration [67]
1496 and 1696 DALYs averted
per million population and net
savings to health system
Health system/20 years Cost saving
16% tax on sugary drinks USA [69]
101 000 DALYS averted. Admin-
istration costs were 0.95% of tax
revenue. Reduction in health care
costs of $24 billion. Return on
 investment of $55 : $1
Health system/10 years Cost saving
Food reformulation to
 reduce salt content
UK (England)
[74]
9758 life years gained in
 population through reduced
coronary heart disease risk; up to
$1017 million saved
Health system/10 years Cost saving
Mandatory labelling of salt
content
UK (England)
[74]
984 life years gained in popula-
tion through reduced coronary
heart disease risk; up to 
$666 million saved 
Health system/10 years Cost saving
Food reformulation to ban
trans-fatty acids
UK (England
and Wales)
[75] 
7900 QALYs gained, and 7200
deaths from coronary heart
 disease averted, with net costs
averted between $93 and 
$383 million (2015)
Health system, 
productivity, informal
care/5 years
Cost saving
Mandatory labelling of
trans-fatty acids
UK (England
and Wales)
[75] 
4000 QALYs gained, and 
3500 deaths from coronary heart
disease averted, with net costs
averted between $32 and 
$167 million (2015)
Consumer standards,
health system,
 productivity, informal
care /5 years
Cost saving
Nationwide salt policy
package: surveillance of 
salt consumption patterns,
 education and awareness
programme and 
salt-reduction strategies in
community eating spaces
(including schools,
 workplaces, hospitals)
Kyrgyzstan
[42]
Positive return on investment:
12.3 to 1 due to productivity
gains. Also 1161 deaths averted
and 15 493 life years gained
Health system,
 productivity/15 years
Cost saving
Public awareness
 campaigning on physical
 activity
Belarus [64]
Positive return on investment: 
5 to 1 due to productivity gains 
Health system & 
productivity/15 years
Cost saving
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Table A5: Other examples of cost saving and cost effective health promoting actions 
Risk factor Intervention Country
Context specific
 examples of return on
investment
Perspective / Time
 period Conclusion
Road  safety 
50% increased
 enforcement of
speeding, drink-
 driving and seat belt
laws
Norway
[84]
4.4, 3.3 and 2.6% reduc-
tion in fatalities. Benefit to
cost ratio of 8, 9.3 and 13
to 1 respectively
Lost productivity, 
police & traffic system/
1 year
Cost saving
Early childhood 
development  
Programme to pro-
mote social, emo-
tional and
behavioural develop-
ment in areas of high
risk for poor child-
hood development
Canada
[80]
Improved education and
mental health outcomes
for children; reduced use
of special educational
needs services, reduced
parental depression,
 reduced crime. Benefit to
cost ratio 2.5:1
Health, education and
social services/7 years
Cost saving
Early childhood 
development  
Parenting 
 programmes to
 prevent long-term
behavioural prob-
lems in at-risk
 children
UK [81]
Significant reduction in
long-term behavioural and
mental health problems in
adulthood. Benefit to cost
ratio of at least 8:1
Health, education,
 social services,
 criminal justice/
25 year
Cost saving
Fall prevention
Home assessments
for fall hazards for
older people
UK [23]
Positive return on
 investment from health
and social care perspective
of 3.17: 1. With societal
benefits this is 7.34:1. 
Health, social care,
 society/2 years
Cost saving
Workplace
health
 promotion
Provision of universal
workplace physical
and mental health
promotion
 programmes
UK [83]
Significant reduction in
 absenteeism and presen-
teeism; reduced contact
with health care systems.
Benefit to cost ratio 9:1 
Business, health/1 year Cost saving
Workplace
health
 promotion
Provision of universal
workplace mental
well-being
 programmes
EU 
countries
[82]
Significant reduction in
 absenteeism and presen-
teeism; reduced contact
with health care systems.
Benefit to cost ratio 28:1 
Business, health, 
social welfare, wider
economy/5 years
Cost saving
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